AstraZeneca upbeat on progress with Lynparza and Calquence
14th Aug 2019 07:32
(Sharecast News) - AstraZeneca announced positive results from the phase 3 'PAOLA-1' trial in women with advanced ovarian cancer on Wednesday, alongside its partner MSD.
Read moreThursday broker round-up
27th Jun 2019 11:16
(Sharecast News) - Rightmove: UBS downgrades to sell with a target price of 505p.
Read moreAstraZeneca reveals positive overall survival results from Imfinzi trial
27th Jun 2019 08:28
(Sharecast News) - Biopharmaceutical company AstraZeneca revealed some positive overall survival results from its Phase III CASPIAN trial with Imfinzi, a human monoclonal antibody.
Read moreAstraZeneca gets three new drug approvals in Japan
19th Jun 2019 07:29
(Sharecast News) - AstraZeneca announced three new drug approvals in Japan on Wednesday, with the first for 'Breztri Aerosphere' (budesonide/glycopyrronium/ formoterol fumarate) - formerly PT010 - as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD).
Read moreAstraZeneca secures another European indication for 'Lynparza'
18th Jun 2019 07:28
(Sharecast News) - AstraZeneca and its partner MSD announced on Tuesday that the European Commission (EC) has approved 'Lynparza' (olaparib) as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
Read moreAstraZeneca upbeat on latest 'Calquence' trial data
17th Jun 2019 07:24
(Sharecast News) - AstraZeneca announced detailed results from the interim analysis of the phase 3 'ASCEND' trial on Monday, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read moreThursday broker round-up
6th Jun 2019 12:40
(Sharecast News) - EI Group: Berenberg downgrades to hold with a target price of 220p.
Read moreAstraZeneca leukaemia drug meets trial end-point
6th Jun 2019 08:34
(Sharecast News) - AstraZeneca said on Thursday its Calquence leukaemia drug had met the primary endpoint of a phase 3 trial and would allow it to file for regulatory approval later this year.
Read moreTuesday broker round-up
4th Jun 2019 13:55
(Sharecast News) - NewRiver: Berenberg downgrades to hold with a target price of 248p.
Read moreAstraZeneca searching for successor to chairman Johansson, reports say
4th Jun 2019 09:11
(Sharecast News) - AstraZeneca has begun the search for a new chairman as the role's current incumbent Leif Johansson looks set to end his seven year spell at the Anglo-Swedish outfit, according to a report from Sky News.
Read moreMonday broker round-up
3rd Jun 2019 12:07
(Sharecast News) - Ferguson: Peel Hunt upgrades to add with a target price of 5,430p.
Read moreTrials show AstraZeneca's Lynparza delaying pancreatic cancer progression
3rd Jun 2019 07:46
(Sharecast News) - AstraZeneca announced on Monday that its Lynparza pancreatic cancer drug has returned positive phase three trial results, doubling the amount of patients with no disease progression.
Read moreFriday broker round-up
24th May 2019 13:23
(Sharecast News) - SafeChange International Group: Berenberg downgrades to hold with a target price of 436p.
Read moreMonday broker round-up
13th May 2019 12:34
(Sharecast News) - Marks & Spencer: Citigroup upgrades to buy with a target price of 330p.
Read moreFriday broker round-up
10th May 2019 13:00
(Sharecast News) - Auto Trader: Citigroup downgrades to neutral with a target price of 580p.
Read more